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Evidence has indicated that failed antitumor immunity is dominated by immunosuppressive mecha-
nisms within the tumor microenvironment. In this issue of Immunity, Peng et al. (2007) add to this list
by describing tumor-infiltrating gd T cells that have regulatory function.Substantial evidence has been ac-
cumulated indicating that immuno-
suppressive mechanisms within the
solid-tumor microenvironment provide
a major barrier to effective antitumor
immunity. One such mechanism ap-
pears to be through the accumula-
tion of CD4+CD25+Foxp3+ regulatory
T (Treg) cells. Treg cells have been
shown to be present at increased
numbers in both the peripheral blood
and among the tumor-infiltrating lym-
phocyte (TIL) population in both mu-
rine models and in patients with any
of several histologies of cancer. Mech-
anistically, murine models of Treg cell
depletion (usually with CD25 mono-
clonal antibody) have demonstrated
improved immune-mediated tumor
control, arguing that they are function-
ally important. Their role directly within
the tumor microenvironment is sup-
ported by experiments in which anti-
CD25 was injected directly into the
tumor, and this facilitated tumor re-
gression. In addition, two-photon
in vivo imaging has demonstratedthat Treg cells can suppress the cyto-
lytic activity of activated CD8+ T cells
in a target tissue through an indirect
mechanism that prevents lysis but
not conjugate formation with target
cells (Mempel et al., 2006). Both natu-
ral thymically derived Treg cells and
peripherally induced Treg cells have
been implicated in tumor models, the
latter of which is consistent with the
high amounts of transforming growth
factor b (TGF-b) observed to be pro-
duced in the tumor microenvironment.
Although there are not yet definitive
mechanistic data showing improved
clinical response with Treg cell deple-
tion in human cancer patients, one
study has shown a greater induction
of antitumor effector T cells when
Treg cell numbers were reduced by
the administration of a CD25-targeted
toxin (Dannull et al., 2005).
However,whetherCD4+CD25+FoxP3+
Treg cells represent the only lympho-
cyte population involved in suppress-
ing effector T cell function within the
tumor microenvironment is not clear.ImmunityA role for B cells in suppressing T cell-
dependent tumor rejection has been
identified in several murine model sys-
tems (Qin et al., 1998). Interleukin10
(IL-10)-producing CD8+ T cells, and
CD4CD8 T cells, also have been
identified (Shevach, 2006) that appear
to inhibit the activation of conventional
CD8+ T cells in the tumor context. In
this issue of Immunity, Peng et al.
(2007) provide convincing evidence
that gd T cell receptor (TCR)-express-
ing T cells derived from the tumor
microenvironment can have potent
suppressive activity toward conven-
tional T cells both in vitro and in vivo,
an observation that could have impor-
tant clinical relevance.
gd T cells have been implicated as
participants in multiple facets of anti-
tumor immune responses, predomi-
nantly as positive regulators. In murine
studies in vivo, gd T cells were found to
be recruited to tumor sites rapidly,
appearing before ab T cells and pro-
ducing high amounts of interferon-g
(IFN-g). Deficiency of gd T cells27, August 2007 ª2007 Elsevier Inc. 185
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cells against tumor antigens, arguing
for a positive innate role for gd T cells
in this system. Intraepithelial gd T cells
also have been shown to control cuta-
neous tumor development in mice
(Girardi et al., 2001). In human cancer
patients, increased numbers of gd
T cells have been observed both in
the circulation and in the tumor micro-
environment. In multiple experimental
models, these cells showed high cyto-
lytic activity and produced inflamma-
tory cytokines such as IFN-g. In some
instances, major histocompatibility
complex (MHC)-non-restricted cyto-
lytic activity against tumor cells that
appears to be mediated through NK
receptor family members has been ob-
served. Human gd T cells expressing
the activating receptors NKp44 and
NKG2D have been described, the ex-
pression of which could mediate this
effect (Groh et al., 1999; von Lilien-
feld-Toal et al., 2006). Thus, gd T cells
can exert important effector functions
against tumors as well. Collectively,
these and other similar data have sug-
gested that gd T cells could represent
a useful cellular constituent of the
immune system to recruit into antitu-
mor immune responses to help pro-
mote tumor control, either through
innate recognition as a bridge to adap-
tive immunity or as effector cells for
direct tumor cell killing. However, not
all data support this positive role. In
one murine model, transplanted B16
melanoma was better controlled in
mice lacking gd T cells (Ke et al., 2003),
arguing that in some settings, gd cells
could be detrimental.
Peng et al. characterized a series of T
cell clones derived from TIL popula-
tions isolated from human breast can-
cers. Surprisingly, a large fraction of
these clones expressed the gd rather
than ab TCR, were CD8aa homodi-
mer positive, and produced IFN-g in
a TCR-dependent but MHC-non-re-
stricted fashion. Direct analysis from
tumor cell suspensions confirmed that
12%–69% of T cells in breast tumor
samples were gd T cells, arguing that
this high percentage was not an artifact
of the T cell cloning method employed.
Based on the high percentage of these
cells in the tumors and the fact that the
tumors were growing progressively,
Peng et al. examined whether these T
cells might have suppressive function.
Indeed, these TIL-derived gd cells
strongly inhibited the activation of con-
ventional T cells in vitro, comparable to
the effect seen with CD25+ Treg cells.
Phenotypically, they were distinct
fromTregcells in that they lacked theex-
pression of Foxp3, GITR, and CD25.
Functionally, the suppressive activity
was mediated through soluble factors
Figure 1. Model of Immune EvasionMechanismswithin the TumorMicroenvironment
Extrinsic suppression by gd T cells has been integrated along with previously defined mechanisms
that include inhibition by Treg cells, the engagement of PD-1 by tumor-expressed PD-L1, anergy
due to deficient expression of B7-1 and B7-2 by tumor cells and antigen-presenting cells, and
amino acid catabolism through indoleamine-2,3-dioxygenase (IDO) and arginase.186 Immunity 27, August 2007 ª2007 Elsevier Inc.but not via TGF-b or IL-10. In addi-
tion to the inhibitory activity against T
cells, these gd T cell clones also pre-
vented the maturation of dendritic cells,
arguing that they could impair antitu-
mor immunity at multiple levels. Thus,
the mechanism of inhibition by tumor-
reactive gd T cells might be unique.
Wang and colleagues previously
had identified a series of TIL-derived
CD25+ Treg cells specific for mela-
noma antigens and observed the ex-
pression of Toll-like receptor 8 (TLR8)
at the mRNA level by those cells
(Peng et al., 2005). The addition of a
TLR8-engaging polyguanosine oligo-
nucleotide (poly-G) prevented sup-
pression by those Treg cells, pointing
toward a potential therapeutic strategy
for countering immune suppression by
antitumor Treg cells in vivo. Surpris-
ingly, in Peng et al., the expression of
TLR8 transcripts was similarly ob-
served on TIL-derived gd T cells, and
as in the case of CD25+ Treg cells,
the addition of poly-G prevented sup-
pression in vitro. By using lentiviral-
encoded shRNAs for specific signaling
molecules, they demonstrated a ne-
cessity for MyD88, IRAK4, TRAF6,
p38 MAP kinase, and IKKa and IKKb
in the reversal of suppression by poly-
G. Although the details of this signaling
pathway, and the putative transcrip-
tional targets controlled by it, remain
unclear, these results clearly support
a signaling role for poly-G in these
experiments.
There are several important limita-
tions of the experiments by Peng
et al. First, the T cell suppression as-
says were performed only with TIL-de-
rived gd T cells that were expanded ini-
tially with high doses of IL-2 (1000 U/
ml). It is conceivable that the culture
conditions used for generating the
clones contributed to their suppressive
phenotype. Similar experiments with
bulk gd T cells directly isolated from tu-
mor sites without in vitro expansion will
provide useful confirmatory informa-
tion. Second, the expression of TLR8
by these gd cells has not been demon-
strated at the protein level. The lack of
good antibodies for the identification
of TLR8 by flow cytometry has ham-
pered the ability to convincingly show
the expression of this receptor on T
cell subsets. Third, the mechanism by
Immunity
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conventional T cells has not been eluci-
dated. The observation that suppres-
sion occurs through a soluble factor
should enable biochemical purification
of this inhibitory molecule, a pursuit
that should receive critical attention in
the future. Despite these caveats, the
characterization of the suppressive
effect of TIL-derived gd T cells is an im-
portant observation that expands our
knowledge of the immunosuppressive
activities within the tumor microenvi-
ronment. An overview of key mecha-
nisms is illustrated in Figure 1.
One final consideration is a chicken
and egg issue: Are gd T cells intrinsi-
cally regulatory or do they become so
under the influence of the tumor micro-
environment? TGF-b has been shown
to contribute to the generation of induc-
ible Foxp3+ Treg cells from naive CD4+
conventional T cells, and it is conceiv-
able that regulatory gd T cells could
be induced through a similar mecha-Balancing Muco
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The molecular mechanism of acu
this issue of Immunity, Lim et al.
the expression of plasminogen a
In Homer’s Odyssey, the protagonist
Odysseus must negotiate his boat
between the multiheaded Scylla and
the whirlpool generating Charybdis or
otherwise succumb to one of these
threats. A similar balance must be
achieved in mucosal immunity: eradi-
cate the offending pathogen without
substantial end-organ injury. Lung in-
fections rank at the top and account
for more than 6% of the total global
burden of disease in 2002 (Mizgerd,
2006). Although antibiotics may im-nism. Assuming that regulatory gd T
cells arise under the condition of
chronic inflammation at tumor sites, it
is possible that they also might be gen-
erated in other situations of chronic
immune stimulation, such as with per-
sistent viral infections. Other immune
suppressive mechanisms at play in
the tumor microenvironment, such as
the expression of PD-L1(B7-H1), the
presence of indoleamine-2,3-dioxyge-
nase, and infiltration with Foxp3+ Treg
cells have indeed been observed to
be prevalent in the situation of chronic
infection, such as inHIV-infected lymph
nodes. A more general role for gd regu-
latory T cells in other in vivo settings will
be of interest to pursue in the future.
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